Jim Stallard, MA

Researchers have shed light on how an important treatment for early-stage bladder cancer enters cancer cells to eradicate them.

Memorial Sloan-Kettering researchers have shown for the first time that administering a growth factor called interleukin-7 can help patients regenerate T cells more quickly after stem cell transplantation.

Memorial Sloan-Kettering’s colorectal cancer team has developed online prediction tools that assess disease risk following surgery, enabling patients and physicians to make better treatment decisions.

With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.

Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).

Memorial Sloan-Kettering researchers have performed the first large-scale genetic analysis of several pediatric cancers, identifying mutations and potential targets for therapies to treat the cancers.